New drug combo tested for advanced cancers in asian patients

NCT ID NCT03433898

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers like stomach, liver, and lung cancer. The study is now complete, but results are not yet public.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ezabenlimab (also called BI 754091) and BI 754111
What this could lead to: If this works, it could point toward a new treatment option for certain advanced cancers like stomach, liver, or lung cancer.
What could go wrong: This is a very early (Phase I) study focused on safety and dosing, not on proving the drugs work. Many early-stage cancer drugs fail to show enough benefit in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer gastric cancer gastroesophageal junction adenocarcinoma neoplasm non-small cell lung carcinoma pediatric hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

Asan Medical Center

Seoul, 05505, South Korea
Chang Gung Memorial Hospital(Linkou)

Taoyuan, 333, Taiwan
Japanese Foundation for Cancer Research

Tokyo, Koto-ku, 135-8550, Japan
Kanagawa Cancer Center

Kanagawa, Yokohama, 241-8515, Japan
NCKUH

Tainan, 70403, Taiwan
National Cancer Center Hospital

Tokyo, Chuo-ku, 104-0045, Japan
National Cancer Center Hospital East

Chiba, Kashiwa, 277-8577, Japan
National Taiwan University Hospital

Taipei, 10002, Taiwan
Saitama Cancer Center

Saitama, Kitaadachi-gun, 362-0806, Japan
Seoul National University Hospital

Seoul, 03080, South Korea
Severance Hospital

Seoul, 03722, South Korea
Shizuoka Cancer Center

Shizuoka, Sunto-gun, 411-8777, Japan
Taipei Veterans General Hospital

Taipei, 11217, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.